Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13,206Revenue $M634Net Margin (%)-13.5Altman Z-Score7.9
Enterprise Value $M13,195EPS $-0.5Operating Margin %-6.3Piotroski F-Score5
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-13.5Higher ROA y-yY
Price/Book14810-y EBITDA Growth Rate %--Quick Ratio4.9Cash flow > EarningsY
Price/Sales19.75-y EBITDA Growth Rate %--Current Ratio4.9Lower Leverage y-yY
Price/Free Cash Flow338y-y EBITDA Growth Rate %-54.5ROA % (ttm)-9.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M186ROIC % (ttm)-66.1Gross Margin Increase y-yN

Gurus Latest Trades with INCY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
INCYVanguard Health Care Fund 2015-12-31 Add0.08%$100.21 - $126.46
($111.45)
$ 71.00-36%Add 4.15%9,615,828
INCYKen Fisher 2015-12-31 Add$100.21 - $126.46
($111.43)
$ 71.00-36%Add 2.23%14,818
INCYVanguard Health Care Fund 2015-09-30 Reduce-0.04%$95.16 - $131.47
($112.12)
$ 71.00-37%Reduce -1.90%9,233,028
INCYJoel Greenblatt 2015-09-30 Reduce-0.01%$95.16 - $131.47
($112.12)
$ 71.00-37%Reduce -53.09%4,861
INCYKen Fisher 2015-09-30 Add$95.16 - $131.47
($112.12)
$ 71.00-37%Add 5.84%14,495
INCYVanguard Health Care Fund 2015-06-30 Reduce-0.15%$88.46 - $110.15
($103.32)
$ 71.00-31%Reduce -7.50%9,411,543
INCYJoel Greenblatt 2015-06-30 Buy 0.01%$88.46 - $110.15
($103.32)
$ 71.00-31%New holding10,363
INCYKen Fisher 2015-06-30 Reduce$88.46 - $110.15
($103.32)
$ 71.00-31%Reduce -7.90%13,695
INCYMariko Gordon 2014-12-31 Sold Out -0.05%$45.6 - $78.89
($65.73)
$ 71.008%Sold Out0
INCYKen Fisher 2014-12-31 Add$45.6 - $78.89
($65.29)
$ 71.009%Add 97.08%14,870
INCYVanguard Health Care Fund 2014-09-30 Add0.07%$45.35 - $56.59
($50.13)
$ 71.0042%Add 6.08%10,174,343
INCYMariko Gordon 2014-09-30 Add$45.35 - $56.59
($50.13)
$ 71.0042%Add 6.55%25,283
INCYKen Fisher 2014-09-30 Reduce$45.35 - $55.78
($50.07)
$ 71.0042%Reduce -38.28%7,545
INCYVanguard Health Care Fund 2014-06-30 Add0.68%$43.1 - $56.39
($50.98)
$ 71.0039%Add 95.66%9,591,143
INCYMariko Gordon 2014-06-30 Reduce-0.19%$43.1 - $56.39
($50.98)
$ 71.0039%Reduce -78.93%23,728
INCYGeorge Soros 2014-06-30 Sold Out -0.01%$43.1 - $56.39
($50.98)
$ 71.0039%Sold Out0
INCYKen Fisher 2014-06-30 Buy $43.1 - $56.39
($50.98)
$ 71.0039%New holding12,225
INCYVanguard Health Care Fund 2014-03-31 Add0.07%$49.94 - $68.83
($62.06)
$ 71.0014%Add 9.97%4,901,968
INCYMariko Gordon 2014-03-31 Reduce-0.03%$49.94 - $68.83
($62.06)
$ 71.0014%Reduce -12.67%112,623
INCYGeorge Soros 2014-03-31 Buy 0.01%$49.94 - $68.83
($61.83)
$ 71.0015%New holding23,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

INCY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


INCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SWAIN PAULA JEVP, Human Resources 2016-01-15Sell13,531$76.96-7.74view
Levy Richard SEVP, Chief Drug Dev Officer 2016-01-06Sell3,937$101.86-30.3view
Siegel Eric H.EVP, General Counsel 2015-12-10Sell1,936$107.96-34.23view
Levy Richard SEVP, Chief Drug Dev Officer 2015-12-07Sell3,937$106.18-33.13view
FRIEDMAN PAUL ADirector 2015-11-18Sell225,000$113.83-37.63view
Siegel Eric H.EVP, General Counsel 2015-11-10Sell2,222$104.86-32.29view
Levy Richard SEVP, Chief Drug Dev Officer 2015-11-06Sell3,936$116.51-39.06view
Wenqing YaoEVP, Discovery Medicinal and P 2015-11-03Sell5,786$124.78-43.1view
Siegel Eric H.EVP, General Counsel 2015-10-13Sell2,222$101.49-30.04view
Levy Richard SEVP, Chief Drug Dev Officer 2015-10-06Sell3,937$122.29-41.94view

Quarterly/Annual Reports about INCY:

    News about INCY:

    Articles On GuruFocus.com
    The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
    Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
    Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
    Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
    Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
    Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
    Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
    Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
    Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
    Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 

    More From Other Websites
    Despite Target Cuts, Analysts Stick With Incyte for Big Upside Jan 30 2016
    A Bad Day for Biotech as Celgene, Incyte Tumble Jan 28 2016
    Incyte Halts Phase II Jakafi-Stivarga Combination Study Jan 28 2016
    Top Analyst Upgrades and Downgrades: Boeing, eBay, Facebook, Incyte, Kinder Morgan, PayPal,... Jan 28 2016
    Technical Roundup on Biotechnology Equities -- Incyte, Juno Therapeutics, Amicus Therapeutics, and... Jan 28 2016
    Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with... Jan 27 2016
    Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with... Jan 27 2016
    INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 26 2016
    Incyte to Report Fourth Quarter/Year-End Financial Results Jan 21 2016
    Incyte to Report Fourth Quarter/Year-End Financial Results Jan 21 2016
    Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis Jan 20 2016
    Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs Jan 20 2016
    What Makes Incyte (INCY) a Strong Sell? Jan 20 2016
    Coverage initiated on Incyte by Credit Suisse Jan 20 2016
    [$$] Eli Lilly Seeks Approval for Rheumatoid-Arthritis Drug Jan 19 2016
    Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib... Jan 19 2016
    Incyte's stock surges after receiving milestone payment from Eli Lilly Jan 19 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK